逆行下腔静脉灌注用于全主动脉弓置换术(RIVP-TARS):多中心随机对照试验研究方案
本研究为多中心、计算机生成随机、评估者盲、平行组、优效性设计试验,拟纳入636例择期全主动脉弓置换术患者,按1:1随机分为中度低温循环停止联合选择性顺行脑灌注组与联合逆行下腔静脉灌注组,主要结局为早期死亡与重大并发症的复合终点,按意向性分析。
要点
- 拟纳入636例全主动脉弓置换术患者,1:1随机分组。
- 主要结局为早期死亡与截瘫、术后肾衰竭、严重肝功能障碍及胃肠道并发症的复合终点。
- 旨在评估逆行下腔静脉灌注联合顺行脑灌注是否优于单纯顺行脑灌注。
核心结论
- 本研究旨在评估逆行下腔静脉灌注联合顺行脑灌注在中度低温全主动脉弓置换术中是否较单纯顺行脑灌注带来更优结局。
- 研究旨在为逆行下腔静脉灌注用于急性A型主动脉夹层行全主动脉弓置换术患者提供高质量证据。
研究设计与样本
- 多中心、计算机生成随机、评估者盲、平行组、优效性设计试验。
- 计划纳入636例择期全主动脉弓置换术患者,按1:1随机分组。
- 中度低温循环停止组接受中度低温下选择性顺行脑灌注;逆行下腔静脉灌注组接受中度低温下逆行下腔静脉灌注联合选择性顺行脑灌注。
- 所有患者按意向性分析方案分析。
关键数值与推荐
- 主要结局为早期死亡与重大并发症的复合终点,重大并发症包括截瘫、术后肾衰竭、严重肝功能障碍和胃肠道并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During total aortic arch replacement surgery (TARS) for patients with acute type A aortic dissection, the organs in the lower body, such as the viscera and spinal cord, are at risk of ischemia even when antegrade cerebral perfusion (ACP) is performed. Combining ACP with retrograde inferior vena caval perfusion (RIVP) during TARS may improve outcomes by providing the lower body with oxygenated blood. METHODS: This study is designed as a multicenter, computer-generated, randomized controlled, assessor-blind, parallel-group study with a superiority framework in patients scheduled for TARS. A total of 636 patients will be randomized on a 1:1 basis to a moderate hypothermia circulatory arrest (MHCA) group, which will receive selective ACP with moderate hypothermia during TARS; or to an RIVP group, which will receive the combination of RIVP and selective ACP under moderate hypothermia during TARS. The primary outcome will be a composite of early mortality and major complications, including paraplegia, postoperative renal failure, severe liver dysfunction, and gastrointestinal complications. All patients will be analyzed according to the intention-to-treat protocol. DISCUSSION: This study aims to assess whether RIVP combined with ACP leads to superior outcomes than ACP alone for patients undergoing TARS under moderate hypothermia. This study seeks to provide high-quality evidence for RIVP to be used in patients with acute type A aortic dissection undergoing TARS. TRIAL REGISTRATION: Clinicaltrials.gov, ID: NCT03607786 . Registered on 30 July 2018.
引用
- Lin J, Tan Z, Yao H, et al. Retrograde Inferior Vena caval Perfusion for Total Aortic arch Replacement Surgery (RIVP-TARS): study protocol for a multicenter, randomized controlled trial. Trials. 2019. PMID: 31014386. doi:10.1186/s13063-019-3319-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。